Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Purchased by CANADA LIFE ASSURANCE Co

CANADA LIFE ASSURANCE Co grew its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 14.6% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 259,831 shares of the medical equipment provider's stock after acquiring an additional 33,137 shares during the quarter. CANADA LIFE ASSURANCE Co owned about 0.13% of Zimmer Biomet worth $27,422,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of ZBH. Dean Investment Associates LLC grew its stake in shares of Zimmer Biomet by 20.0% in the 4th quarter. Dean Investment Associates LLC now owns 29,253 shares of the medical equipment provider's stock valued at $3,090,000 after buying an additional 4,866 shares during the period. Farringdon Capital Ltd. acquired a new position in shares of Zimmer Biomet in the 4th quarter valued at $517,000. NewEdge Advisors LLC increased its position in shares of Zimmer Biomet by 72.6% during the 4th quarter. NewEdge Advisors LLC now owns 4,713 shares of the medical equipment provider's stock worth $498,000 after purchasing an additional 1,983 shares during the last quarter. NFJ Investment Group LLC purchased a new stake in Zimmer Biomet in the 4th quarter valued at about $5,363,000. Finally, Dodge & Cox lifted its position in Zimmer Biomet by 12.0% in the fourth quarter. Dodge & Cox now owns 19,118,436 shares of the medical equipment provider's stock valued at $2,019,480,000 after buying an additional 2,044,645 shares during the last quarter. Institutional investors and hedge funds own 88.89% of the company's stock.

Insider Buying and Selling

In other Zimmer Biomet news, SVP Lori Winkler sold 1,443 shares of Zimmer Biomet stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total value of $150,649.20. Following the transaction, the senior vice president now owns 8,768 shares in the company, valued at $915,379.20. This trade represents a 14.13 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.70% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on ZBH. Royal Bank of Canada reduced their price target on shares of Zimmer Biomet from $130.00 to $125.00 and set an "outperform" rating on the stock in a research note on Friday, February 7th. BTIG Research restated a "buy" rating on shares of Zimmer Biomet in a research note on Monday, April 14th. Stifel Nicolaus lifted their price objective on Zimmer Biomet from $130.00 to $138.00 and gave the company a "buy" rating in a research note on Thursday, January 23rd. JMP Securities reissued a "market outperform" rating and set a $140.00 target price on shares of Zimmer Biomet in a research note on Friday, February 7th. Finally, Raymond James dropped their target price on Zimmer Biomet from $126.00 to $119.00 and set an "outperform" rating for the company in a research report on Friday, February 7th. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $124.15.

Zimmer Biomet Stock Performance

ZBH traded up $0.12 on Friday, hitting $101.62. 578,679 shares of the company traded hands, compared to its average volume of 1,660,939. The company has a 50 day moving average of $105.82 and a 200-day moving average of $106.57. Zimmer Biomet Holdings, Inc. has a 12-month low of $93.10 and a 12-month high of $123.96. The stock has a market capitalization of $20.10 billion, a PE ratio of 22.83, a PEG ratio of 1.95 and a beta of 0.84. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share for the quarter, topping analysts' consensus estimates of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same quarter in the previous year, the firm posted $2.20 EPS. Sell-side analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be paid a $0.24 dividend. The ex-dividend date is Monday, March 31st. This represents a $0.96 annualized dividend and a yield of 0.94%. Zimmer Biomet's payout ratio is currently 21.57%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.